Endo USA v. Baxter International: Epinephrine Patent Case Dismissed Without Prejudice
Endo USA and Endo Operations Limited filed suit against Baxter International in the Northern District of Illinois, asserting three patents covering epinephrine compositions and containers. The case ended after just 99 days when plaintiffs declined to oppose Baxter’s motion to dismiss for lack of subject matter jurisdiction, with each party bearing its own costs.
Jurisdiction kills Endo’s epinephrine case before it reaches the merits
On March 5, 2025, Endo USA, Inc. and Endo Operations Limited filed an infringement action against Baxter International, Inc. in the U.S. District Court for the Northern District of Illinois before Judge Franklin U. Valderrama. The complaint asserted three patents — US11207280B2, US11071719B2, and US12133837B2 — all directed to epinephrine compositions and container technologies, a segment of the critical injectable drug market.
The case closed on June 12, 2025, after only 99 days. Baxter moved to dismiss for lack of subject matter jurisdiction, and Endo filed a notice of non-opposition, effectively conceding the jurisdictional argument. Judge Valderrama granted the motion, dismissing all claims and defenses without prejudice, with each party bearing its own attorneys’ fees and costs. The without-prejudice designation preserves Endo’s right to refile if jurisdictional deficiencies are cured.
A dismissal at 99 days — before any substantive merits ruling — is notable for how quickly the jurisdictional issue proved fatal to the action at this stage. The public record does not reveal the precise nature of the standing or jurisdictional defect, nor whether Endo intends to refile in a different forum or after remedying the deficiency. The unresolved magistrate report and recommendation on a temporary restraining order suggests the parties had been actively litigating before the jurisdictional issue crystallised.
Filing to Dismissed without Prejudice in 99 days
99-day lifespan — well below median patent case duration of 2–3 years
Dismissed without prejudice: what the ruling means for both parties
Lack of subject matter jurisdiction — no merits reached
The dismissal was granted on Baxter’s motion asserting lack of subject matter jurisdiction — meaning the court found it had no authority to hear the case as presented, not that Endo’s patent claims lacked merit. Endo’s non-opposition is consistent with either a standing defect (e.g., improper plaintiff entity) or a ripeness issue. No infringement or validity determinations were made.
Jurisdictional dismissal onlyWithout prejudice: Endo retains the right to refile
A dismissal without prejudice does not extinguish Endo’s infringement claims or invalidate the three asserted patents. Endo may refile in federal court once any jurisdictional defect is remedied — for example, by joining the correct patent owner entity or establishing sufficient Article III standing. The patents remain in force and enforceable against Baxter or any other party.
Claims survive; refiling possibleBaxter escapes on procedure — merits exposure remains
Baxter achieved dismissal without any finding on infringement or invalidity, and without paying attorneys’ fees. However, the without-prejudice nature of the dismissal means Baxter’s exposure to these three epinephrine patents is not eliminated. If Endo cures the jurisdictional defect and refiles, Baxter will face the same substantive claims in a properly constituted action.
No merits win for BaxterEpinephrine IP landscape remains unsettled after this ruling
Because no court ruled on the validity or scope of Endo’s three epinephrine patents, competitors and product teams in the injectable drug space cannot treat this dismissal as clearing the path. The patents covering epinephrine compositions and containers remain active and potentially enforceable. Companies commercialising epinephrine delivery systems should maintain FTO vigilance on all three patent numbers.
FTO exposure unchangedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Endo USA, Inc. | Company | Pharmaceutical company — holder of US11207280B2, US11071719B2, and US12133837B2Search in Eureka ↗ |
| Defendant | Baxter International, Inc. | Company | Baxter International, Inc. — global medical products and injectable drug manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | Constance Lee | Attorney | Counsel for Endo USA, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gregory A Morris | Attorney | Counsel for Endo USA, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James Lee Lovsin | Attorney | Counsel for Endo USA, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert Shaffer | Attorney | Counsel for Endo USA, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McDonnell, Boehnen, Hulbert & Berghoff LLP | Law Firm | Representing Endo USA, Inc.Search in Eureka ↗ |
| Plaintiff law firm | O’Melveny & Myers LLP | Law Firm | Representing Endo USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Emily Larrimer Savas | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant counsel | Jacob Christopher Britz | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant counsel | James T Peterka | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant counsel | Scott Patrick Clark | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant counsel | Terrence Patrick Canade | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant counsel | Timothy Flynn Peterson | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant law firm | Buchanan, Ingersoll & Rooney PC | Law Firm | Representing Baxter International, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Franklin U. Valderrama | Judge | Illinois Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order reflects a purely procedural resolution: Endo’s non-opposition to Baxter’s jurisdictional motion meant Judge Valderrama had no basis to retain the case. The dismissal without prejudice and fee-neutral cost allocation are consistent with a consensual exit, not a contested defeat. No infringement, validity, or claim construction ruling was made. The termination of the unresolved magistrate TRO report suggests the parties agreed to stand down at this stage, likely preserving optionality for a reconstituted proceeding.
US11207280B2, US11071719B2 & US12133837B2 — Epinephrine Compositions and Containers
The three asserted patents — US11207280B2 (App. No. US16/821785), US11071719B2 (App. No. US16/788831), and US12133837B2 (App. No. US17/526786) — relate to epinephrine compositions and containers, covering a critical segment of the injectable emergency drug market. Epinephrine, used to treat anaphylaxis and cardiac arrest, is subject to intense formulation and delivery innovation. The staggered application numbers suggest a continuation or related patent family, indicating Endo pursued layered claim coverage across both composition and container dimensions.
Endo’s decision to assert all three patents simultaneously against Baxter International — a major manufacturer of injectable drug products — signals that these patents are viewed as strategically significant for protecting market position in epinephrine delivery. For competitors developing pre-filled syringes, autoinjectors, or alternative epinephrine container systems, this patent family represents a meaningful freedom-to-operate consideration regardless of the procedural outcome in this particular case. The patents remain in force and enforceable.
Should you run an FTO against US11207280B2, US11071719B2 & US12133837B2?
Any company developing, manufacturing, or commercialising epinephrine injectable products — including pre-filled syringes, vials, autoinjector systems, or container closure innovations — should treat Endo’s three-patent family as active FTO risk. The procedural dismissal of this case does not constitute a finding that any product is non-infringing or that the patents are invalid. R&D teams designing epinephrine delivery systems should audit their formulations and container designs against all three patent claim sets before launch.
PatSnap Eureka’s FTO Search Agent can map your product specifications against the claims of US11207280B2, US11071719B2, and US12133837B2 in minutes — identifying potential overlap, design-around opportunities, and citation networks across the broader Endo epinephrine portfolio. Eureka also tracks subsequent litigation filings, allowing your team to monitor whether Endo refiles this action in a reconstituted or amended proceeding.
Run a freedom-to-operate analysis on US11207280B2 to assess your product’s exposure
Run FTO in Eureka →Similar epinephrine and injectable drug patent cases in U.S. district courts
Explore related pharmaceutical patent infringement cases involving epinephrine formulations, injectable drug compositions, and container patents litigated in U.S. district courts.
What this case signals for the injectable drug IP landscape
A 99-day jurisdictional dismissal in a pharmaceutical patent case rarely ends the story — especially when the patents remain in force.
Jurisdictional dismissals preserve all future enforcement options for patent holders
Endo’s non-opposition to dismissal is not an admission of weakness on the merits. Without-prejudice dismissals allow plaintiffs to restructure their case — correcting standing, adding co-owners, or refiling in a different forum. Competitors should not assume the litigation risk has passed simply because this case closed.
Each party bearing own costs signals a negotiated or strategic exit
Fee-neutral dismissals in pharmaceutical patent cases are consistent with a mutually agreed procedural exit rather than a contested defeat. The parties may be negotiating licensing terms, restructuring ownership of the patents, or preparing a more jurisdictionally robust refiling. The unresolved TRO motion suggests urgency on Endo’s side that likely persists.
Endo v Baxter — key questions answered
Endo USA and Endo Operations Limited sued Baxter International in the Northern District of Illinois asserting three epinephrine patents (US11207280B2, US11071719B2, US12133837B2). After 99 days, the case was dismissed without prejudice when Endo did not oppose Baxter’s motion to dismiss for lack of subject matter jurisdiction. No merits ruling was issued.
A dismissal without prejudice does not invalidate the patents or preclude Endo from refiling. All three asserted patents remain in force. Endo may bring a new action once any jurisdictional defect — such as a standing or ownership issue — is remedied. Competitors cannot treat the dismissal as a clearance of infringement risk.
The public record does not specify the precise jurisdictional defect. Common bases in pharmaceutical patent cases include lack of standing (e.g., a co-owner of the patent not joined as plaintiff), ripeness issues, or a dispute over which Endo entity held enforceable rights. Endo’s non-opposition suggests the defect was not easily contested at the time of filing.
Endo asserted US11207280B2 (App. No. US16/821785), US11071719B2 (App. No. US16/788831), and US12133837B2 (App. No. US17/526786). All three patents relate to epinephrine compositions and containers — a patent family consistent with continued prosecution strategy to secure layered protection over formulation and delivery innovations.
Endo was represented by McDonnell, Boehnen, Hulbert & Berghoff LLP and O’Melveny & Myers LLP, with attorneys including Constance Lee, Gregory A. Morris, James Lee Lovsin, and Robert Shaffer. Baxter was represented by Buchanan, Ingersoll & Rooney PC, with attorneys Emily Larrimer Savas, Jacob Christopher Britz, James T. Peterka, Scott Patrick Clark, Terrence Patrick Canade, and Timothy Flynn Peterson.
PatSnap Eureka searches patents and litigation data to answer instantly.